Building the Foundation Behind Our WorkOur core projects remain the same. They are still central to our mission.
But strong projects need a strong foundation behind them.Like many early-stage nonprofits, we have been carrying much of this work through volunteer effort. We now need a stronger operational base for coordination, applications, reporting, communication, and project support.
That is why we have added a new project to our site: Building the Operational Foundation Behind Every Project.
This effort supports all of our other work.
We have completed the core specification of Interceptor v0, defining the internal structure of the system at the current stage of development.
Interceptor is being developed as a dynamic state model of a pediatric cancer patient. The system represents the patient as an evolving process described by a structured state vector and governed by mode-dependent dynamics.
The current specification introduces three key components:
First, a 10-component state vector that captures both tumor-related processes and the child’s physiological condition. This allows the model to track tumor progression and host response within a unified framework.
Second, a mode-switching structure that separates baseline periods, active treatment phases, and recovery intervals. Each mode is associated with different system dynamics, reflecting real clinical conditions.
Third, a strict separation between observations and interventions. Measured data (laboratory values, imaging-derived features, clinical events) are treated independently from clinical actions (therapy, procedures, supportive care),ensuring a consistent and interpretable modeling approach.
A key design principle of Interceptor is the joint modeling of tumor dynamics and host physiology. The system integrates both domains into a single evolving representation.
The goal of this specification is to establish a controlled, testable framework that can be incrementally expanded and validated.
To make our work more visible and easier to follow, the personal Facebook profile of our founder, Sergei Oleshkevich, has now been opened to the public and set to Professional Mode. In addition to updates on our website, we will now also share selected project news, milestones, and progress updates on Facebook. This gives supporters and interested readers another simple way to follow the development of OncoHelper AI and our work in pediatric oncology.
In the four months since receiving official U.S. nonprofit status, OncoHelper AI has moved from formation into execution. Research teams are now in place for our three core programs, and work is underway: our AI platform, the zinc plus iron platform, and our PARP inhibitor program. We have reached the point where small early contributions unlock real momentum.
If you support better outcomes in pediatric oncology, your donation helps us keep the work moving forward.
We Expanded the Platform to Zinc Plus Iron
Over the past weeks, the project team substantially refined this program and strengthened the scientific and implementation plan. The project remains in development, but the architecture of the work is now clearly defined: a chickpea-derived peptide–mineral platform designed to deliver better-tolerated, more bioavailable supplementation for supportive care, starting with zinc.
A major update is that an iron track has been added to the program. In parallel with the zinc–peptide work, the team will identify and characterize iron-binding peptides from the same chickpea protein platform and define the stability and functional properties of peptide–iron complexes. This creates a practical foundation for future iron-focused formulations, using a shared production and deployment pathway.
Multiple technical discussions were held with professors and research collaborators from California-based universities and other partners to stress-test the plan, confirm feasibility, and tighten the milestone structure. The result is a more rigorous, better-scoped roadmap that links analytical characterization, absorption testing, functional bioactivity assays, and prototype formulation to clear, measurable deliverables.
We are now raising funding to launch laboratory execution and move through the first milestone series toward validated prototypes and regulatory-ready data packages.
